Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19-expressing cells. We previously reported that CTL019 achieved impressive clinical efficacy in patient...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Mueller, Karen Thudium, Maude, Shannon L., Porter, David L., Frey, Noelle, Wood, Patricia, Han, Xia, Waldron, Edward, Chakraborty, Abhijit, Awasthi, Rakesh, Levine, Bruce L., Melenhorst, J. Joseph, Grupp, Stephan A., June, Carl H., Lacey, Simon F.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2017
主題:
Lymphoid Neoplasia
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5731220/
https://ncbi.nlm.nih.gov/pubmed/28935694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-786129
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料